Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 28, 2026, 11:02 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 553–576 of 9,654 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Human Clear all
Terminated Not applicable Interventional Results available

A Study of INFUSE Bone Graft (BMP-2) in the Treatment of Tibial Pseudarthrosis in Neurofibromatosis Type 1 (NF1)

NCT02718131
View directory record Official record
Conditions
NF1, Congenital Pseudarthrosis of Tibia
Interventions
INFUSE Bone Graft (BMP-2), Control Group
Device · Procedure
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
2 Years to 18 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
15
States / cities
Birmingham, Alabama • Los Angeles, California • Washington D.C., District of Columbia + 10 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2021 · Synced Oct 28, 2026, 11:02 AM EDT
Completed Phase 1 Interventional

A Study to Evaluate the Safety and Tolerability of AB154 in Participants With Advanced Malignancies

NCT03628677
View directory record Official record
Conditions
Solid Tumor, Unspecified, Adult
Interventions
Domvanalimab, Zimberelimab
Drug
Lead sponsor
Arcus Biosciences, Inc.
Industry
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
6
States / cities
Los Angeles, California • Hinsdale, Illinois • Huntersville, North Carolina + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2025 · Synced Oct 28, 2026, 11:02 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Development of a Training Intervention to Improve Mental Health Treatment Effectiveness and Engagement for Youth With Documented Mental Health Disparities

NCT05626231
View directory record Official record
Conditions
Knowledge, Attitudes, Practice
Interventions
Training Intervention
Behavioral
Lead sponsor
Boston College
Other
Eligibility
12 Years and older
Enrollment
286 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
1
States / cities
Chestnut Hill, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 25, 2025 · Synced Oct 28, 2026, 11:02 AM EDT
Recruiting Phase 1 Interventional

Trial to Evaluate the Safety & Tolerability of JBZ-001 in Pts With Advanced Solid and Hematological Malignancies

NCT06801002
View directory record Official record
Conditions
Solid Tumor
Interventions
JBZ-001
Drug
Lead sponsor
Jabez Bioscience, Inc
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
2
States / cities
Columbus, Ohio • West Valley City, Utah
Source: ClinicalTrials.gov public record
Updated Apr 24, 2026 · Synced Oct 28, 2026, 11:02 AM EDT
Withdrawn Phase 1 Interventional

CT-011 and p53 Genetic Vaccine for Advanced Solid Tumors

NCT01386502
View directory record Official record
Conditions
Breast Cancer, Colon Cancer, Pancreatic Cancer, Sarcoma, Ovarian Cancer
Interventions
p53: 264-272 peptide, CT-011
Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 99 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 28, 2026, 11:02 AM EDT
Recruiting Phase 1Phase 2 Interventional

ADG126 in Combination With Pembrolizumab in Patients With Advanced/Metastatic Solid Tumors

NCT05405595
View directory record Official record
Conditions
Advanced/Metastatic Solid Tumors
Interventions
ADG126, Pembrolizumab (KEYTRUDA®), Standard of Care (Trifluridine/Tipiracil-Bevacizumab), Standard of care (Fruquintinib)
Drug
Lead sponsor
Adagene Inc
Industry
Eligibility
18 Years and older
Enrollment
186 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
7
States / cities
Scottsdale, Arizona • Duarte, California • Irvine, California + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 7, 2026 · Synced Oct 28, 2026, 11:02 AM EDT
Terminated Phase 1Phase 2 Interventional

Dose Escalation and Expansion Study of SAR444200-based Regimen in Adult Participants With Advanced Solid Tumors

NCT05450562
View directory record Official record
Conditions
Neoplasm
Interventions
SAR444200, Atezolizumab
Biological
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
4
States / cities
Los Angeles, California • New York, New York • Providence, Rhode Island + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 14, 2026 · Synced Oct 28, 2026, 11:02 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

Study of a Human Metapneumovirus/Respiratory Syncytial Virus mRNA Vaccine Candidate Encapsulated in a Lipid Nanoparticle-based Formulation in Adults Aged 60 Years and Older

NCT06686654
View directory record Official record
Conditions
Human Metapneumovirus Immunization, Respiratory Syncytial Virus Immunization
Interventions
Investigational hMPV/RSV vaccine, Investigational hMPV vaccine (monovalent), Investigational RSV vaccine (monovalent), Licensed RSV Vaccine, Placebo, Investigational RSV+hMPV vaccine
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
60 Years and older
Enrollment
1,530 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
24
States / cities
Phoenix, Arizona • Garden Grove, California • Gardena, California + 20 more
Source: ClinicalTrials.gov public record
Updated Dec 11, 2025 · Synced Oct 28, 2026, 11:02 AM EDT
Not yet recruiting Phase 2 Interventional

A Study of the Safety and Exploratory Efficacy of Oral AFA-281 in Patients with Alcohol Use Disorder

NCT06710431
View directory record Official record
Conditions
Alcohol Abuse, Alcohol Abuse/addiction, Anxiety, Pain Threshold, Depression Disorders, Sleep Disorder
Interventions
AFA-281
Drug
Lead sponsor
Afasci Inc
Industry
Eligibility
21 Years to 65 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 29, 2024 · Synced Oct 28, 2026, 11:02 AM EDT
Terminated Not applicable Interventional

Exercise Preconditioning in Ovarian Cancer

NCT05029154
View directory record Official record
Conditions
Ovarian Cancer
Interventions
High intensity interval exercise, Attention control
Behavioral
Lead sponsor
University of Virginia
Other
Eligibility
18 Years and older · Female only
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Jun 12, 2025 · Synced Oct 28, 2026, 11:02 AM EDT
Completed Phase 1 Interventional Results available

Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Voxilaprevir in Adults With Chronic Hepatitis C Virus Infection

NCT02185794
View directory record Official record
Conditions
Hepatitis C Virus Infection
Interventions
Voxilaprevir, Placebo to match voxilaprevir, SOF/VEL
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 65 Years
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
10
States / cities
Costa Mesa, California • DeLand, Florida • Orlando, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2020 · Synced Oct 28, 2026, 11:02 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Identifying Terpenoid- and Carotenoid-modifying Enzymes in the Human Gut

NCT07589166
View directory record Official record
Conditions
Terpene Synthases, Carotenoid Modifying Enzymes
Interventions
No Intervention: Observational Cohort
Other
Lead sponsor
North Carolina State University
Other
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Raleigh, North Carolina
Source: ClinicalTrials.gov public record
Updated May 20, 2026 · Synced Oct 28, 2026, 11:02 AM EDT
Completed Phase 2 Interventional Results available

Therapy for Pediatric Relapsed or Refractory Precursor B-Cell Acute Lymphoblastic Leukemia and Lymphoma

NCT01700946
View directory record Official record
Conditions
Recurrent B-Cell Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood B-Lymphoblastic Lymphoma
Interventions
dexamethasone, vincristine sulfate, rituximab, clofarabine, cyclophosphamide, etoposide, aldesleukin, pegaspargase, methotrexate, mercaptopurine, cytarabine, mitoxantrone, teniposide, vinblastine, natural killer cell infusion, laboratory biomarker analysis, therapeutic hydrocortisone, allogeneic hematopoietic stem cell transplantation, CliniMACS
Drug · Biological · Other + 2 more
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Up to 21 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2021
U.S. locations
3
States / cities
San Diego, California • Memphis, Tennessee • Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Sep 28, 2022 · Synced Oct 28, 2026, 11:02 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Measurement of Bite Force in Humans

NCT00223327
View directory record Official record
Conditions
Dental Pulp Necrosis, Periapical Periodontitis
Interventions
Not listed
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
16 Years to 60 Years
Enrollment
89 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2008
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Mar 9, 2012 · Synced Oct 28, 2026, 11:02 AM EDT
Completed Phase 2 Interventional Results available

Study of BMN 110 in Pediatric Patients < 5 Years of Age With Mucopolysaccharidosis IVA (Morquio A Syndrome)

NCT01515956
View directory record Official record
Conditions
Mucopolysaccharidosis IVA, Morquio A Syndrome, MPS IVA
Interventions
BMN 110
Drug
Lead sponsor
BioMarin Pharmaceutical
Industry
Eligibility
Up to 5 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
2
States / cities
Oakland, California • Manhasset, New York
Source: ClinicalTrials.gov public record
Updated Aug 10, 2017 · Synced Oct 28, 2026, 11:02 AM EDT
Completed Phase 1 Interventional

Study of Antibody Drug Conjugate in Patients With Advanced Breast Cancer Expressing HER2

NCT02952729
View directory record Official record
Conditions
Advanced Breast Cancer, Advanced Nonsmall Cell Lung Cancer, Advanced Gastric Cancer
Interventions
XMT-1522
Drug
Lead sponsor
Mersana Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
5
States / cities
Tampa, Florida • Boston, Massachusetts • Nashville, Tennessee + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 24, 2021 · Synced Oct 28, 2026, 11:02 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Low Dose Molecular Breast Imaging as a Screening Tool for Women With Dense Breasts

NCT01925170
View directory record Official record
Conditions
Breast Cancer
Interventions
Molecular Breast Imaging, Conventional Mammography, Technetium (99mTc) sestamibi
Device · Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
40 Years and older · Female only
Enrollment
1,638 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2013
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 19, 2014 · Synced Oct 28, 2026, 11:02 AM EDT
Terminated Phase 1 Interventional

A Study of ATG-031 in Advanced Solid Tumors or B-cell Non-Hodgkin Lymphomas

NCT06028373
View directory record Official record
Conditions
Advanced Solid Tumors, B-cell Non-Hodgkin Lymphomas
Interventions
ATG-031
Drug
Lead sponsor
Antengene Biologics Limited
Industry
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
4
States / cities
San Francisco, California • Aurora, Colorado • New Haven, Connecticut + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Oct 28, 2026, 11:02 AM EDT
Not listed Phase 2Phase 3 Interventional

Study of AAVrh10-h.SGSH Gene Therapy in Patients With Mucopolysaccharidosis Type IIIA (MPS IIIA)

NCT03612869
View directory record Official record
Conditions
Mucopolysaccharidosis Type IIIA
Interventions
LYS-SAF302
Drug
Lead sponsor
LYSOGENE
Industry
Eligibility
6 Months and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
4
States / cities
Orange, California • Minneapolis, Minnesota • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 31, 2021 · Synced Oct 28, 2026, 11:02 AM EDT
Available No phase listed Expanded access

Early Access Treatment With Tralesinidase Alfa in Mucopolysaccharidosis Type IIIB (Sanfilippo Syndrome Type B)

NCT07733856
View directory record Official record
Conditions
Mucopolysaccharidosis Type IIIB, MPS IIIB (Sanfilippo B Syndrome)
Interventions
Tralesinidase alfa (TA)
Drug
Lead sponsor
Spruce Biosciences
Industry
Eligibility
12 Months and older
U.S. locations
1
States / cities
Oakland, California
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 28, 2026, 11:02 AM EDT
Completed Phase 3 Interventional Results available

6-month Comparison of Morning Lantus Versus Neutral Protamine Hagedorn Insulin in Young Children With Type 1 Diabetes

NCT00993473
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Insulin glargine (HOE901), Neutral Protamine Hagedorn (NPH) insulin, Insulin lispro
Drug
Lead sponsor
Sanofi
Industry
Eligibility
1 Year to 6 Years
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
8
States / cities
Sacramento, California • San Diego, California • Greenwood Village, Colorado + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2012 · Synced Oct 28, 2026, 11:02 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Inflammation and Threat Sensitivity in PTSD

NCT03048929
View directory record Official record
Conditions
Posttraumatic Stress Disorder
Interventions
Typhoid Vi Polysaccharide Vaccine, Placebo
Biological
Lead sponsor
University of California, San Francisco
Other
Eligibility
30 Years to 60 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
2
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 13, 2021 · Synced Oct 28, 2026, 11:02 AM EDT
Completed Phase 1 Interventional

Treatment of SCID Due to ADA Deficiency With Autologous Transplantation of Cord Blood or Hematopoietic CD 34+ Cells After Addition of a Normal Human ADA cDNA by the EFS-ADA Lentiviral Vector

NCT02022696
View directory record Official record
Conditions
Adenosine Deaminase Deficiency, ADA-SCID
Interventions
Lentiviral Gene Transfer
Genetic
Lead sponsor
National Human Genome Research Institute (NHGRI)
NIH
Eligibility
1 Year to 65 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 27, 2017 · Synced Oct 28, 2026, 11:02 AM EDT
Completed Phase 3 Interventional Results available

Study of Recombinant Human N-acetylgalactosamine 4-sulfatase (rhASB) in Patients With MPS VI

NCT00067470
View directory record Official record
Conditions
Mucopolysaccharidosis VI
Interventions
Placebo, N-acetylgalactosamine 4-sulfatase
Drug
Lead sponsor
BioMarin Pharmaceutical
Industry
Eligibility
7 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
1
States / cities
Novato, California
Source: ClinicalTrials.gov public record
Updated Dec 24, 2009 · Synced Oct 28, 2026, 11:02 AM EDT